FDA allows a Phase II trial of Athersys' MultiStem

11/10/2010 | MassDevice.com (Boston)

The FDA has granted approval to Athersys to conduct a midstage trial of MultiStem, an experimental stem cell therapy derived from bone marrow, in patients with inflammatory bowel disease. Athersys CEO Gil Van Bokkelen said Pfizer will shoulder the cost of the 126-patient study as part of a development and marketing deal signed in December.

View Full Article in:

MassDevice.com (Boston)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Eastern Zone Sales Director
Regenesis Biomedical
White Plains, NY
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Associate Director, Regulatory Affairs - Promotional Review
Novo Nordisk
Princeton, NJ